Best Pharma Stocks in March 2025: Laurus Labs, Glenmark Pharma and More- Based on 5 Yr CAGR

India’s pharmaceutical sector continues to grow rapidly, with the market valued at $50 billion in FY 2023-24. Domestic consumption stands at $23.5 billion, while exports contribute $26.5 billion, solidifying India’s global presence.

The industry benefits from strong government initiatives, including the establishment of seven National Institutes of Pharmaceutical Education & Research (NIPERs) and the “National Policy on Research & Development and Innovation in Pharma-MedTech Sector.”

These efforts aim to foster innovation, enhance regulatory support, and strengthen India’s position as a leader in drug discovery and medical devices.

Amid this evolving landscape, several pharma stocks, including Laurus Labs and Glenmark Pharmaceuticals, have demonstrated impressive 5-year CAGR, making them key players to watch in March 2025.

Top 10 Pharma Sector Stock List In March 2025 – 5 Year CAGR Basis

Note: The list of top pharma stocks in India listed in the stock market here are sorted as per the 5-yr CAGR as of March 3, 2025.

Overview of the 5 Best Pharma Company Stocks for March 2025

1. Laurus Labs

Laurus Labs is a leading pharmaceutical and biotechnology company specialising in APIs, formulations, and synthesis services. It focuses on innovation-driven growth in segments like antiretrovirals, oncology, and custom synthesis.

Laurus Labs’ Q3 FY25 EBITDA margin expanded by 500 basis points to 20.2%, the highest since Q4 FY23. Net profit surged to ₹92 crore from ₹23 crore last year, driven by an 18.5% YoY revenue growth to ₹1,415 crore.

Key metrics:

• ROE: 3.93%
• ROCE: 7.95%

2. Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals is a global pharmaceutical company specialising in generics, specialty, and over-the-counter medicines. It focuses on innovation-driven research in dermatology, respiratory, and oncology segments.

Glenmark Pharmaceuticals reported a strong recovery in Q3FY25, posting a net profit of ₹347.9 crore compared to a net loss of ₹351.3 crore last year. Revenue surged 35.1% YoY to ₹3,387.6 crore, reflecting robust operational performance.

Key metrics:

• ROE: -16.98%
• ROCE: 11.12%

3. Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries is the world’s fourth-largest specialty generic pharmaceutical company and India’s top pharma company. It focuses on developing, manufacturing, and marketing a broad range of formulations and APIs across multiple therapeutic segments.

Sun Pharmaceutical Industries reported a 15% YoY rise in consolidated net profit to ₹2,903.4 crore in Q3 FY25. Revenue grew 10% YoY to ₹13,675.5 crore, driven by strong performance in domestic and emerging markets.

Key metrics:

• ROE: 15.15%
• ROCE: 16.58%

4. Cipla Ltd

Cipla is a leading global pharmaceutical company focused on developing affordable and high-quality medicines across various therapeutic areas. It specialises in respiratory, anti-retroviral, urology, and chronic disease segments, with a strong presence in over 80 countries.

Cipla reported a 49% YoY surge in consolidated net profit to ₹1,571 crore in Q3 FY25. Revenue grew 7% to ₹7,073 crore, driven by strong operational performance.

Key metrics:

• ROE: 21.23%
• ROCE: 15.54%

5. Zydus Lifesciences Ltd

Zydus Lifesciences is a leading Indian pharmaceutical company focused on innovation-driven healthcare solutions, including generics, biologics, and vaccines. It has a strong presence in global markets, specialising in critical therapies like cardiovascular, diabetes, and oncology.

Zydus Lifesciences reported a 30% YoY rise in net profit to ₹1,023 crore in Q3 FY25, supported by strong forex gains. Revenue grew 17% to ₹5,269 crore, reflecting robust business performance.

Key metrics:

• ROE: 20.91%
• ROCE: 19.44%

Pharmaceutical Companies Sorted by Debt-to-Equity Ratio

Note: The list of top pharma stocks in India listed in the stock market here are sorted as per the Debt-to-Equity as of March 03, 2025.

Best Pharma Sector Stock List In India In March 2025 – Net Profit Margin Basis

Note: The list of top pharma stocks in India listed in the stock market here are sorted as per the net profit margin as of March 3, 2025.

Conclusion

The Indian pharmaceutical sector has shown strong growth, supported by domestic demand, exports, and government initiatives. Based on key financial metrics, companies like Laurus Labs, Glenmark Pharmaceuticals and others have demonstrated solid performance over the past five years.

The data highlights their financial stability and market standing, providing insights into their past growth trends. Investors and stakeholders can use these metrics to assess the sector’s recent performance within the evolving industry landscape.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.